Comparing the emerging KRAS G12C clinical data in NSCLC with chemotherapy and immunotherapy in KEYNOTE-189, with the caveat that patient characteristics differ between trials, activity of the KRAS G12C inhibitors in delaying disease progression appears more robust than standard platinum doublet therapy (PFS 4.9 months) however less than pembrolizumab (PD-1 inhibitor) plus platinum doublet therapy (PFS 9.0 months). Here, KRAS is linked to non-small cell lung carcinoma.